The Filing Desk

Zymeworks

ZYME · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

ZYME · Last close · November 13, 2026
$26.24
Value Zymeworks yourself

Zymeworks' revenue rose 38.9% to $106 million in fiscal 2025. Its operating margin was −87.3%, up from −179.7% a year earlier. Free cash flow was −$35 million. It paid out $42 million in dividends and buybacks. The diluted share count fell 0.6%.

ZYMEWORKS INC. Latest fiscal year ended December 31, 2025 10-K filed March 2, 2026 · 0001937653-26-000015 Updated
Revenue
$106M
38.9%
Operating margin
−87.3%
92.3 pts
Net income
−$81M
 
Free cash flow
−$35M
 
Return on equity
−26.7%
3.8 pts
Market cap
$2.0B
Nov 13 close
P/E
50.5x
On $0.52 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Zymeworks does

Zymeworks is a biotechnology company that describes itself as managing a portfolio of licensed healthcare assets while developing its own drug candidates. Its pipeline is built on two technology platforms: multispecific antibody therapeutics, which are antibodies that bind more than one target, and antibody-drug conjugates, which attach a toxic drug to an antibody. It aims at cancer, inflammation and autoimmune disease.

Its strategy is to collect royalties and milestone payments on drugs that partners develop and sell. Its licensed products include Ziihera (zanidatamab-hrii) and pasritamig. It depends on partners, including Jazz, BeOne and Johnson and Johnson, to develop and sell zanidatamab and other candidates. It also seeks new partners to share the cost and risk of late-stage development.

Zymeworks says that as its royalty portfolio matures it may use spare cash to buy back its own shares, and that it will also invest in acquisitions and its own research. It calls this royalty-led strategy unproven.

Its biggest risks, as it describes them

  • Its royalty-focused strategy of gathering licensed assets is unproven and may not work.
  • It depends on partners such as Jazz, BeOne and Johnson and Johnson to develop and sell zanidatamab and other candidates.
  • Deals it makes to buy assets could disrupt the business or dilute shareholders.
  • Its candidates may fail in trials or lose priority, so it may not build a pipeline.
  • It may struggle to find new partners, which face strong competition for the same deals.
From Zymeworks's annual report on Form 10-K, filed March 2, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Zymeworks lost money in fiscal 2025: a net loss of $81 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments253492374226229
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio4.0x5.7x7.4x3.4x5.9x
Quick ratio4.0x5.7x7.4x3.4x5.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Zymeworks' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Zymeworks says to expect

  • Full year 2026: revenue and adjusted EBITDAThe Company has increased its 2026 financial guidance for total revenue to be between $337 million and $351 million (previously between $278 million and $292 million) and adjusted EBITDA to be between $176 million and $190 million (previously between $114 million and $128 million), excluding the impact of any future transactions.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 9, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Zymeworks shares on the open market, and 4 insiders sold $4.7 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jan 12, 2026Kenneth GalbraithChair & CEO, DirectorSold30,424$22.67$689,712Form 4
Jan 12, 2026Paul Andrew MooreChief Scientific OfficerSold9,560$22.67$216,725Form 4
Jan 12, 2026Jeffrey T L SmithEVP & Chief Medical OfficerSold9,310$22.67$211,058Form 4
Jan 12, 2026Mark HollywoodEVP & Chief Operating OfficerSold6,120$22.67$138,740Form 4
Jan 5, 2026Kenneth GalbraithChair & CEO, DirectorSold54,343$25.10$1.4 millionForm 4
Jan 5, 2026Paul Andrew MooreChief Scientific OfficerSold20,110$25.10$504,761Form 4
Jan 5, 2026Jeffrey T L SmithEVP & Chief Medical OfficerSold10,538$25.10$264,504Form 4
Dec 22, 2025Kenneth GalbraithChair & CEO, DirectorSold47,528$27.02$1.3 millionForm 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−240.5%−146.5%6.3%
Altman Z''2.84−1.97−3.24
Accruals ratio−0.1%−2.4%−11.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassFailPass
Share count didn't riseFailFailPass
Gross margin rose———
Revenue rose relative to assetsFailPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Zymeworks side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
ZymeworksFY2538.9%−87.3%−32.6%———
Zevra TherapeuticsFY25350.9%−59.1%−2.3%−218.8%—5Compare
UroGen PharmaFY2521.4%−113.7%−148.2%——2Compare
Nurix TherapeuticsFY2554.0%−340.2%−313.7%———Compare
Eton PharmaceuticalsFY25104.9%−1.1%12.8%−1.9%1.4x4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue39274127676106
Revenue growth—−31.5%1,446.0%−81.6%0.4%38.9%
Gross profit——————
Research and development171200209144135137
Operating income−188−216130−138−137−92
Net income−181−212124−119−123−81
Diluted EPS (US$)−3.58−4.611.90−1.72−1.62−1.08
Diluted shares (millions)505265697675
Cash flow
Cash from operations−151−192144−118−110−33
Capital expenditure4128222
Free cash flow−156−205136−121−112−35
Dividends paid000000
Share buybacks00003042
Acquisitions000000
Stock-based compensation2911481828
Balance sheet at fiscal year end
Cash and short-term investments242253492374226229
Debt incl. finance leases——————
Total assets—389649581463346
Total liabilities—14015611612478
Shareholders' equity410249493465339268
Margins and ratios
Gross margin——————
Operating margin−481.3%−808.2%31.6%−181.6%−179.7%−87.3%
Net margin−463.5%−794.0%30.1%−156.1%−160.8%−76.6%
Free cash flow margin−399.8%−767.8%33.0%−158.9%−146.8%−32.6%
Rule of 40 (growth + FCF margin)—−799.3%1,479.0%−240.5%−146.5%6.3%
Return on capital——————
Return on equity——33.5%−24.8%−30.5%−26.7%
Return on assets——24.0%−19.3%−23.5%−20.0%
Net debt to EBITDA——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Zymeworks' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Zymeworks.